Given the essential roles of both USP22 and USP7 in cancer growth, stemness, DDR, and critical cancer-related oncogenic and tumor suppressor signaling axes such as p53, c-Myc, our findings suggest targeting both USP22 and USP7 will induce broad and synergistic anti-cancer activities, which warrant further investigation. The gene discussed is TP53; the disease is cancer.